PVX108 | SnackSafely.com

Aravax

Aravax Doses First Patient in Phase 2 Peanut Allergy Clinical Trial

News Wire ~ 3rd Party Press Release - 2023/06/01

PVX108 does not contain peanut proteins which put patients at risk of serious side effects.

Test Tubes

FDA Green Lights Phase 2 Trials of PVX108, a Novel Peptide-Driven...

News Wire ~ 3rd Party Press Release - 2022/03/04

Phase 2 study of candidate from Aravax will commence in the US and Australia.

Research

Aravax Presents Additional Positive Phase I Trial Results for PVX108, a...

News Wire ~ 3rd Party Press Release - 2019/06/05

Trial results demonstrate excellent PVX108 safety profile in patients with prior anaphylaxis and current asthma.

Researchers

Phase I Trial for New Peanut Allergy Immunotherapy Results in No...

Dave Bloom - 2019/02/24

Research details phase one study of peptide-based immunotherapy, which is designed to remove risks of acute reactions during treatment.

Researchers

Novel Peanut Allergy Vaccine Begins Phase I Clinical Trials

Dave Bloom - 2017/05/22

Vaccine uses peptides selected from parts of the peanut protein that do not cause life-threatening anaphylactic reactions.

Established in 2011, SnackSafely.com provides straightforward, actionable information to help improve the lives of the estimated 32 million people in the US suffering with food allergies.

We strive to eliminate anaphylaxis by leveraging our on-line properties to educate, advocate, and connect the allergic community with products and services that help toward achieving this goal.

Our blog covers topics of interest to the food allergy community including news reports; ongoing research, clinical studies, trials and progress toward treatment and cure; general advocacy; and advice regarding food safety and school policies.

Please see our Terms of service and Privacy Policy.

SnackSafely.com, PO Box 141, Hillsdale, NJ 07642

©2020 SnackSafely.com Inc. All rights reserved.